Evaluate the Safety and Efficacy of ON101 Cream for the Treatment of Chronic Diabetic Foot Ulcers

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

PHASE3

Total Enrollment

12 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-07-27

Study Completion Date

2022-11-29

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The primary efficacy endpoint for this study is the proportion of subjects with complete closure of Target Ulcer during the 20-week Treatment Phase, which is assessed by the blinded independent evaluator.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Randomized,Double-blind,Placebo-controlled Clinical Study to Explore the Mechanism of Action of ON101 Cream in Patients With DFUs.

NCT04945161

Diabetic Foot Ulcers

COMPLETED NA

Evaluate the Efficacy and Safety of ON101 Cream for the Treatment of Chronic Diabetic Foot Ulcers

NCT01898923

Diabetic Foot

COMPLETED PHASE3

A Research Study to Evaluate the Safety and Potential Efficacy of ON101 Cream for the Treatment of Venous Leg Ulcers.

NCT05322525

Venous Leg Ulcers (VLU)

TERMINATED PHASE4

Retrospective Record-review Study in Patients Who Had Diabetic Foot Ulcer

NCT05135130

Diabetic Foot Ulcer

UNKNOWN

Clinical Evaluation of DCB-WH1 in Healing of Chronic Diabetic Foot Ulcers

NCT00709514

Chronic Diabetic Foot Ulcer

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Chronic Diabetic Foot Ulcers

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

ON101 Cream plus Standard of Care

ON101 cream will be applied twice daily for up to 20 weeks to the Target Ulcer. The SOC will include evaluation to ensure adequate blood flow, wound cleaning, removal of necrotic, infected and/or nonviable tissue by debridement, maintenance of a moist wound environment via regular dressing changes, and management of infection through oral antibiotics, if necessary.

Group Type EXPERIMENTAL

ON101 Cream

Intervention Type DRUG

Active ingredients: Extracts of Plectranthus amboinicus and Centella Asiatica

Vehicle Cream plus Standard of Care

Vehicle cream will be applied twice daily for up to 20 weeks to the Target Ulcer.

The SOC will include evaluation to ensure adequate blood flow, wound cleaning, removal of necrotic, infected and/or nonviable tissue by debridement, maintenance of a moist wound environment via regular dressing changes, and management of infection through oral antibiotics, if necessary.

Group Type PLACEBO_COMPARATOR

Vehicle Cream

Intervention Type OTHER

ON101 Cream Placebo

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

ON101 Cream

Active ingredients: Extracts of Plectranthus amboinicus and Centella Asiatica

Intervention Type DRUG

Vehicle Cream

ON101 Cream Placebo

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Subjects, male or female, aged 18 to 80 years (inclusive) with Type 1 or Type 2 diabetes undergoing therapy for glycemic control using available diabetes drugs including insulin.
2. Subject has a glycosylated hemoglobin, HbA1c ≦ 12%.
3. Presence of at least one diabetic foot ulcer that meets all of the following criteria:

1. A full-thickness ulcer of UTWCS Grade I-A or II-A
2. Ulcer size (area) is \> 1 cm2 and ≤ 20 cm2 (post-debridement at time of screening and randomization)
3. Ulcer is located on or below the malleoli and presents duration of between 6 weeks and 12 months (at time of screening).
4. There is a minimum 3 cm margin between the qualifying Target Ulcer and any other ulcers on the specified foot (post-debridement)
5. No active infection by clinical inspection as defined by IDSA/IWGDF criteria Note: If the subject has more than one qualifying diabetic foot ulcer, the most severe ulcer will be designated as the target ulcer.
4. Subject has adequate vascular perfusion of the affected limb, confirmed by Ankle-Brachial Index (ABI) \> 0.8 and \< 1.3, and transcutaneous pressure of oxygen (TcPO2) \> 30 mmHg on at least one lead.
5. Subject, if female of child-bearing potential, has a negative serum pregnancy test at screening, must not be breastfeeding, and willing to use 2 medically accepted methods of contraception (e.g., barrier contraceptives \[female condom, or diaphragm with a spermicidal gel\], hormonal contraceptives \[implants, injectables, combination oral contraceptives, transdermal patches, or contraceptive rings\], and intrauterine devices) during the study (excluding women who are not of childbearing potential and/or who have been sterilized).
6. Subject should be able to walk and stand on the non-target ulcer limb.
7. Subject is willing to use an off-loading device for the target ulcer on the plantar while ambulation for the duration of the study.
8. Subject / identified caregiver trained on the study procedures is able and willing to comply with study procedures.
9. A signed and dated informed consent form has been obtained from the subject prior to any study-related procedures being performed.

Exclusion Criteria

1. In response to standard of care, ulcer size reduction is \> 30% during the two-week run-in Screening Period (between the first Screening Visit/V0 and Baseline/V2).
2. Ulcers with exposed bone or associated with osteomyelitis. Note: The osteomyelitis should be ruled out by clinical examination (probing of the wound) and X-ray findings.
3. Presence of necrosis, purulence or sinus tracts that cannot be removed by debridement.
4. Body mass index (BMI) \> 42 kg/m2
5. Laboratory values at Screening of:

1. White Blood Cells (WBC) \< 3.0 X 109 cells/L；\> 12.0 X 109 cells/L
2. Liver function studies \[Total bilirubin, aspartate aminotransferase (AST) and alanine transaminase (ALT)\] \> 3x the upper limit of normal
3. Albumin \< 2.5 g/dL
4. Renal function studies \[Serum Creatinine and Urea\] \> 3x the upper limit of normal
6. Presence of any clinically significant medical condition(s) in medical history during screening period that, in the opinion of the investigator, could interfere with wound healing, including but not limited to the following:

1. Acute or unstable Charcot foot
2. Current sepsis
3. Active malignant disease. A subject, who has had a malignant disease in the past, was treated and is currently disease-free, may be considered for study entry.
4. Acquired immune deficiency syndrome (AIDS) or HIV positive.
7. Subject is currently receiving (i.e., within 30 days of randomization visit) or scheduled to receive any of following medication or therapies, could interfere with wound healing during the study.

1. immunosuppressants (including chronic systemic corticosteroids)
2. cytotoxic chemotherapy
3. cytostatic therapy
4. autoimmune disease therapy
5. dialysis
6. lower limb revascularization surgery (e.g., angioplasty, artery bypass surgery)
7. growth factors
8. hyperbaric oxygen therapy
9. bioengineered tissue or skin substitutes
10. application of topical steroids to the ulcer
11. use of any investigational drug(s)
8. Subjects whose non-target ulcer limb is disabled or amputated above the ankle.
9. Subject's target ulcer is located on the plantar foot with all toes amputated.
10. Subjects who need to stand continuously for more than 4 hours / day and have difficulty complying with off-loading instruction.
11. A psychiatric condition (e.g., suicidal ideation), current or chronic alcohol or drug abuse, determined from the subject's medical history, which, in the opinion of the Investigator, may pose a threat to subject compliance.
12. Has any other factor which may, in the opinion of the investigator, compromise participation and/or follow-up in the study.

Minimum Eligible Age

18 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No